Striving To Treat Blinding Retinal Conditions
Striving To Treat Blinding Retinal Conditions
ReVive Biotechnology is a diverse, multidisciplinary, and friendly team motivated to better lives through the advancement of clinical therapeutics. Based in Research Park at the University of Illinois, Urbana-Champaign, the team has access to state-of-the-art laboratories and facilities to carry out their research.
ReVive Biotechnology is a diverse, multidisciplinary, and friendly team motivated to better lives through the advancement of clinical therapeutics. Based in Research Park at the University of Illinois, Urbana-Champaign, the team has access to state-of-the-art laboratories and facilities to carry out their research.
Revive Biotechnology is a diverse, multidisciplinary, and friendly team motivated to better lives through the advancement of clinical therapeutics. Based in Research Park at the University of Illinois, Urbana-Champaign, the team has access to state-of-the-art laboratories and facilities to carry out their research.
WHAT WE DO
With a goal of improving oxygen delivery to hypoxic tissues by utilizing innovative nanotechnology, research and development is currently focused on treatment for central retinal artery occlusion (CRAO) with potential future applications for additional ocular ischemic conditions. Pre-clinical studies have advanced through proof of concept and the team is now working through the regulatory process to achieve FDA approval for this revolutionary therapeutic.
With a goal of improving oxygen delivery to hypoxic tissues by utilizing innovative nanotechnology, research and development is currently focused on treatment for central retinal artery occlusion (CRAO) with potential future applications for additional ocular ischemic conditions. Pre-clinical studies have advanced through proof of concept and the team is now working through the regulatory process to achieve FDA approval for this revolutionary therapeutic.